



Louisiana

Gender Affirming Surgery

Policy # 00643

Original Effective Date: 12/19/2018

Current Effective Date: 10/14/2024

Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc. (collectively referred to as the "Company"), unless otherwise provided in the applicable contract. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

When Services May Be Eligible for Coverage

Coverage for eligible medical treatments or procedures, drugs, devices or biological products may be provided only if:

- *Benefits are available in the member's contract/certificate, and*
- *Medical necessity criteria and guidelines are met.*

Based on review of available data, the Company may consider gender affirming pelvic or gonadal surgery (which may consist of a combination of the following: *hysterectomy, orchiectomy, ovariectomy, or salpingo-oophorectomy*) to be **eligible for coverage.****

Patient Selection Criteria

Coverage eligibility will be considered for gender affirming pelvic or gonadal surgery (which may consist of a combination of the following: *hysterectomy, orchiectomy, ovariectomy, or salpingo-oophorectomy*) when **ALL** of the following criteria are met:

- A. The individual is at least 18 years of age; **AND**
- B. The individual has capacity to make fully informed decisions and consent for treatment; **AND**
- C. The individual has been diagnosed with gender dysphoria (see Policy Guidelines); **AND**
- D. For individuals without a medical contraindication or intolerance, the individual has undergone a minimum of 12 months of continuous hormonal therapy when recommended by a mental health professional and provided under the supervision of a physician; **AND**
- E. If the individual has significant medical or mental health issues present, they must be reasonably well controlled. If the individual is diagnosed with severe psychiatric disorders and impaired reality testing (for example, psychotic episodes, bipolar disorder, dissociative identity disorder, borderline personality disorder), an effort must be made to improve these conditions with psychotropic medications and/or psychotherapy before surgery is contemplated; **AND**

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Gender Affirming Surgery

Policy # 00643

Original Effective Date: 12/19/2018

Current Effective Date: 10/14/2024

- F. Two referrals from qualified mental health professionals[◇] who have independently assessed the individual. If the first referral is from the individual's psychotherapist, the second referral should be from a person who has only had an evaluative role with the individual. Two separate letters, or one letter signed by both (for example, if practicing within the same clinic) are required. The letter(s) must have been signed within 12 months of the request submission.

Based on review of available data, the Company may consider the use of hair removal procedures to treat tissue donor sites for a planned phalloplasty or vaginoplasty procedure to be **eligible for coverage**** when the eligible for coverage criteria for phalloplasty or vaginoplasty procedures below are met.

Based on review of available data, the Company may consider gender affirming genital surgery (which may consist of a combination of the following: *clitoroplasty, labiaplasty, metoidioplasty, penectomy, phalloplasty, scrotoplasty, urethroplasty, vaginectomy, vaginoplasty, or placement of penile or testicular prostheses*)^{◇◇}, to be **eligible for coverage.****

Patient Selection Criteria

Coverage eligibility will be considered for individuals undergoing gender affirming genital surgery (which may consist of a combination of the following: *clitoroplasty, labiaplasty, metoidioplasty, penectomy, phalloplasty, scrotoplasty, urethroplasty, vaginectomy, vaginoplasty, or placement of penile or testicular prostheses*)^{◇◇} when **ALL** of the following criteria are met:

- A. The individual is at least 18 years of age; **AND**
- B. The individual has capacity to make fully informed decisions and consent for treatment; **AND**
- C. The individual has been diagnosed with gender dysphoria (see Policy Guidelines); **AND**
- D. For individuals without a medical contraindication or intolerance, the individual has undergone a minimum of 12 months of continuous hormonal therapy when recommended by a mental health professional and provided under the supervision of a physician; **AND**
- E. Documentation^{◇◇} that the individual has completed a minimum of 12 months of successful continuous full time real-life experience in their new gender, across a wide range of life experiences and events that may occur throughout the year (for example, family events, holidays, vacations, season-specific work or school experiences). This includes coming out to partners, family, friends, and community members (for example, at school, work, and other settings); **AND**

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Gender Affirming Surgery

Policy # 00643

Original Effective Date: 12/19/2018

Current Effective Date: 10/14/2024

- F. Regular participation in psychotherapy throughout the real-life experience when recommended by a treating medical or behavioral health practitioner; **AND**
- G. If the individual has significant medical or mental health issues present, they must be reasonably well controlled. If the individual is diagnosed with severe psychiatric disorders and impaired reality testing (for example, psychotic episodes, bipolar disorder, dissociative identity disorder, borderline personality disorder), an effort must be made to improve these conditions with psychotropic medications and/or psychotherapy before surgery is contemplated; **AND**
- H. Two referrals from qualified mental health professionals[◇] who have independently assessed the individual. If the first referral is from the individual's psychotherapist, the second referral should be from a person who has only had an evaluative role with the individual. Two separate letters, or one letter signed by both (for example, if practicing within the same clinic) are required. The letter(s) must have been signed within 12 months of the request submission.

Based on review of available data, the Company may consider nipple reconstruction, including tattooing, following a gender affirming mastectomy to be **eligible for coverage**** when the eligible for coverage criteria below are met.

Based on review of available data, the Company may consider gender affirming bilateral subcutaneous mastectomy, to be **eligible for coverage.****

Patient Selection Criteria

Coverage eligibility will be considered for gender affirming bilateral subcutaneous mastectomy when **ALL** of the following criteria are met:

- A. The individual is at least 18 years of age (see *Further Considerations* section below for individuals under 18 years of age); **AND**
- B. The individual has capacity to make fully informed decisions and consent for treatment; **AND**
- C. The individual has been diagnosed with gender dysphoria (see Policy Guidelines); **AND**
- D. If the individual has significant medical or mental health issues present, they must be reasonably well controlled. If the individual is diagnosed with severe psychiatric disorders and impaired reality testing (for example, psychotic episodes, bipolar disorder, dissociative identity disorder, borderline personality disorder), an effort must be made to improve these

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Gender Affirming Surgery

Policy # 00643

Original Effective Date: 12/19/2018

Current Effective Date: 10/14/2024

conditions with psychotropic medications and/or psychotherapy before surgery is contemplated; **AND**

- E. One letter, signed by the referring qualified mental health professional who has independently assessed the individual, is required; the letter must have been signed within 12 months of the request submission; **AND**

Further Considerations:

A provider with experience treating adolescents with gender dysphoria may request further consideration of a bilateral mastectomy in an individual under 18 years of age when permitted by state law and when they meet all other bilateral mastectomy criteria (including prior mental health evaluation).

Detailed medical necessity and justification will be required, including time spent living in the desired gender role and duration of testosterone replacement. The WPATH SOC8 provides the following surgical criteria for adolescent individuals:

- a. “Gender diversity/incongruence is marked and sustained over time;
- b. Meets the diagnostic criteria of gender incongruence in situations where a diagnosis is necessary to access health care;
- c. Demonstrates the emotional and cognitive maturity required to provide informed consent/assent for the treatment;
- d. Mental health concerns (if any) that may interfere with diagnostic clarity, capacity to consent, and gender-affirming medical treatments have been addressed; sufficiently so that gender-affirming medical treatment can be provided optimally.
- e. Informed of the reproductive effects, including the potential loss of fertility and the available options to preserve fertility;
- f. At least 12 months of gender-affirming hormone therapy or longer, if required, to achieve the desired surgical result for gender-affirming procedures, including breast augmentation, orchiectomy, vaginoplasty, hysterectomy, phalloplasty, metoidioplasty, and facial surgery as part of gender-affirming treatment unless hormone therapy is either not desired or is medically contraindicated.”

“Given potential shifts in gender-related experiences and needs during adolescence, it is important to establish the young person has experienced several years of persistent gender diversity/incongruence prior to initiating less reversible treatments such as gender-affirming

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Gender Affirming Surgery

Policy # 00643

Original Effective Date: 12/19/2018

Current Effective Date: 10/14/2024

hormones or surgeries.” It should be emphasized that WPATH SOC8 states the condition should be present for “*several years*” to establish the incongruity is “sustained”.

(Further information is available in the Rationale section of this document titled ‘Gender Affirming Surgery in Individuals Under the Age of 18’).

◇ At least one of the professionals submitting a letter must have a doctoral degree (for example, Ph.D., M.D., Ed.D., D.Sc., D.S.W., or Psy.D) or a master’s level degree in a clinical behavioral science field (for example, M.S.W., L.C.S.W., Nurse Practitioner [N.P.], Advanced Practice Nurse [A.P.R.N.], Licensed Professional Counselor [L.P.C.], and Marriage and Family Therapist [M.F.T.]) and be capable of adequately evaluating co-morbid psychiatric conditions. One letter is sufficient if signed by two providers, one of whom has met the specifications set forth above.

◇◇ The medical documentation should include the start date of living full time in the new gender. Verification via communication with individuals who have related to the individual in an identity-congruent gender role, or requesting documentation of a legal name change, may be reasonable in some cases.

Note: Procedures to address postoperative complications of gender affirming surgery (for example, stenosis, scarring, chronic infection, or pain) are not considered separate gender affirming surgery procedures.

Note: Reversal of a prior gender affirming surgery procedure is considered gender affirming surgery and the medical necessity criteria above apply.

When Services Are Considered Not Medically Necessary

The use of gender affirming surgery when patient selection criteria above are not met is considered to be **not medically necessary**.**

When Services Are Not Covered

Based on review of available data, the Company considers gender affirming surgery for **cosmetic** procedures to be **not covered**.**

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Gender Affirming Surgery

Policy # 00643

Original Effective Date: 12/19/2018

Current Effective Date: 10/14/2024

The use of **cosmetic** procedures are considered to be **not covered**** when requested alone or in combination with other procedures to improve the gender specific appearance, including, but not limited to, the following:

- A. Abdominoplasty;
- B. Blepharoplasty;
- C. Breast augmentation;
- D. Brow lift;
- E. Calf implants;
- F. Face lift;
- G. Facial bone reconstruction;
- H. Facial implants;
- I. Gluteal augmentation (implants/lipofilling);
- J. Hair removal (for example, electrolysis or laser), hair reconstruction and hairplasty, when the criteria above have not been met;
- K. Jaw reduction (jaw contouring);
- L. Lip reduction/enhancement;
- M. Lipofilling/collagen injections;
- N. Liposuction;
- O. Nose implants;
- P. Pectoral implants;
- Q. Rhinoplasty;
- R. Thyroid cartilage reduction (chondroplasty);
- S. Voice modification surgery.

Note: Cosmetic procedures are considered an exclusion in most member contracts.

Policy Guidelines

The American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders, Fifth edition (DSM-5) provides criteria for the diagnosis of gender dysphoria. The DSM-5 criteria are widely recognized as the community standard by which individuals suspected of gender dysphoria are evaluated and diagnoses are confirmed. The DSM-5 criteria for gender dysphoria are as follows:

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Gender Affirming Surgery

Policy # 00643

Original Effective Date: 12/19/2018

Current Effective Date: 10/14/2024

Gender dysphoria in Children[◇]

- A. A marked incongruence between one's experienced/expressed gender and assigned gender, of at least 6 months duration, as manifested by at least six of the following (one of which must be Criterion A1):
1. A strong desire to be of the other gender or an insistence that one is the other gender (or some alternative gender, different from one's assigned gender).
 2. In boys (assigned gender), a strong preference for cross dressing or simulating female attire; or in girls (assigned gender), a strong preference for wearing only typical masculine clothing and a strong resistance to wearing of typical feminine clothing.
 3. A strong preference for cross-gender roles in make-believe play or fantasy play.
 4. A strong preference for toys, games, or activities stereotypically used or engaged in by the other gender.
 5. A strong preference for playmates of the other gender.
 6. In boys (assigned gender), a strong rejection of typically masculine toys, games and activities and a strong avoidance of rough and tumble play; or in girls (assigned gender), a strong rejection of typically feminine toys, games and activities.
 7. A strong dislike of one's sexual anatomy.
 8. A strong desire for the primary and/or secondary sex characteristics that match one's experienced gender.
- B. The condition is associated with clinically significant distress or impairment in social, school, or other important areas of functioning.

Gender dysphoria in Adolescents and Adults[◇]

- A. A marked incongruence between one's experienced/expressed gender and assigned gender, of at least 6 months duration, as manifested by at least two of the following:
1. A marked incongruence between one's experienced/expressed gender and primary and/or secondary sex characteristics (on in young adolescents, the anticipated secondary sex characteristics).
 2. A strong desire to be rid of one's primary and/or secondary sex characteristics because of a marked incongruence with one's experienced/expressed gender (or in young adolescents, a desire to prevent the development of the anticipated secondary sex characteristics).
 3. A strong desire for the primary and/or secondary sex characteristics of the other gender.

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Gender Affirming Surgery

Policy # 00643

Original Effective Date: 12/19/2018

Current Effective Date: 10/14/2024

4. A strong desire to be of the other gender (or some alternative gender different from one's assigned gender).
 5. A strong desire to be treated as the other gender (or some alternative gender different from one's assigned gender).
 6. A strong conviction that one has the typical feelings and reactions of the other gender (or some alternative gender different from one's assigned gender).
- B. The condition is associated with clinically significant distress or impairment in social, occupational, or other important areas of functioning.

◇ From: American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition Text Revision. February 2022. Washington, DC. Pages 511-520.

The World Professional Association for Transgender Health's (WPATH) Standards of Care (SOC) for the Health of Transgender and Gender Diverse People, 8th Version (2022) (SOC8) provides the most recent recommendations for care of transgender and gender diverse (TGD) individuals. The SOC8 states,

The SOC-8 guidelines are intended to be flexible in order to meet the diverse health care needs of TGD people globally. While adaptable, they offer standards for promoting optimal health care and for guiding the treatment of people experiencing gender incongruence.

and

Clinical departures from the *SOC* may come about because of a patient's unique anatomic, social, or psychological situation; an experienced health professional's evolving method of handling a common situation; a research protocol; lack of resources in various parts of the world; or the need for specific harm-reduction strategies.

In the WPATH SOC8 references the World Health Organization's International Classification of Diseases (ICD)-11 as the appropriate criteria to establish the presence or absence of gender incongruence. It must be noted that the ICD-11 is not widely used in the U.S. for diagnostic purposes. The generally accepted reference used by providers in the U.S. for the diagnosis of psychiatric and psychological conditions is the American Psychiatric Association's (APA) Diagnostic and Statistical Manual of Mental Disorders (DSM), version 5 text revision (DSM-5-TR). As such, the DSM-5-TR

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Gender Affirming Surgery

Policy # 00643

Original Effective Date: 12/19/2018

Current Effective Date: 10/14/2024

criteria are used in this document in lieu of the ICD-11. It should also be noted that the WPATH SOC8 have been created for a global audience and intended for use across a wide variety of cultures and healthcare systems. With that in mind, some recommendations should be re-assessed in the context of U.S.-based medical and surgical settings.

Any variations from recommendations by WPATH within this guideline may reflect where SOC standards are, for example, not based on published medical evidence.

Background/Overview

This document addresses gender affirming surgery (also known as sex affirmation surgery, gender or sex reassignment surgery, gender or sex confirmation surgery). Gender affirming surgery is a treatment option for gender dysphoria, a condition in which a person experiences persistent incongruence between gender identity and sexual anatomy at birth. Gender affirming surgery is not an isolated intervention; it is part of a complex process involving multiple medical, psychiatric and psychologic, and surgical specialists working in conjunction with each other and the individual to achieve successful behavioral and medical outcomes.

Rationale/Source

This medical policy was developed through consideration of peer-reviewed medical literature generally recognized by the relevant medical community, U.S. Food and Drug Administration approval status, nationally accepted standards of medical practice and accepted standards of medical practice in this community, technology evaluation centers, reference to federal regulations, other plan medical policies, and accredited national guidelines.

Hormone Therapy

While this document does not address the medical necessity of gender-affirming hormone therapy (GAHT), GAHT plays an important role in the gender transition process by altering body hair, breast size or development, skin appearance and texture, body fat distribution, the size and function of sex organs, and other characteristics, including voice deepening. Use of GAHT prior to some surgical procedures has been identified as an important factor in improved functional, cosmetic, and psychological outcomes and this should be taken into serious consideration prior to any surgical procedures. GAHT should be administered under medical supervision. The WPATH SOC8 guidelines is supportive of this approach, stating the following:

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Gender Affirming Surgery

Policy # 00643

Original Effective Date: 12/19/2018

Current Effective Date: 10/14/2024

GAHT leads to anatomical, physiological, and psychological changes. The onset of the anatomic effects (e.g., clitoral growth, vaginal mucosal atrophy) may begin early after the initiation of therapy, and the peak effect is expected at 1–2 years (T’Sjoen et al., 2019). Depending upon the surgical result required, a period of hormone treatment may be required (e.g., sufficient clitoral virilization prior to metoidioplasty/phalloplasty) or preferred for psychological reasons, anatomical reasons, or both (breast growth and skin expansion prior to breast augmentation, softening of skin and changes in facial fat distribution prior to facial GAS) (de Blok et al., 2021).

For individuals who are not taking hormones prior to surgical interventions, it is important surgeons review the impact of this on the proposed surgery.

The optimal duration of hormone therapy prior to a surgical procedure has not been the subject of extensive, rigorous study. However, existing evidence indicates that the maximum physiological effects are usually reached at 1-2 years, but may take longer. For individuals without a medical contraindication or intolerance, a minimum of 12 months of continuous GAHT, when clinically recommended, is likely to improve outcomes before some surgical procedures.

Introduction to Surgical Procedures

The criteria sets provided above in the Clinical Indications section include several shared criterion applicable to the decision making process for the majority of situations where an individual may be seeking gender affirming surgical procedures, including the following:

- A. The individual is at least 18 years of age
- B. The individual has capacity to make fully informed decisions and consent for treatment
- C. The individual has been diagnosed with gender dysphoria
- D. If the individual has significant medical or mental health issues present, they must be reasonably well controlled. If the individual is diagnosed with severe psychiatric disorders and impaired reality testing (for example, psychotic episodes, bipolar disorder, dissociative identity disorder, borderline personality disorder), an effort must be made to improve these conditions with psychotropic medications and/or psychotherapy before surgery is contemplated

The age of 18 is the “age of majority” in the U.S. and is considered the age at which an individual is recognized as an adult and assumes specific rights and responsibilities. An individual seeking

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Gender Affirming Surgery

Policy # 00643

Original Effective Date: 12/19/2018

Current Effective Date: 10/14/2024

gender affirming surgical procedures should have established sufficient cognitive and physical maturity to make important decisions related to self-determination, including medical decisions.

The capacity to make fully informed decisions and consent for treatment is an important consideration for individuals seeking gender affirming care, especially when medical and surgical decisions have the potential for serious long-term impact on an individual's physical, psychological, reproductive, and social function. Capacity for consent includes several factors, including the ability to understand the nature of the treatment options, the ability to reason through the risks and benefits of their treatment options, the ability to understand and appreciate the potential long-term ramifications of their decisions, and the ability to effectively communicate their choices. These attributes are especially important in the realm of gender affirming surgical procedures, given the serious risks and long-term impacts they have. The issue of capacity to consent in adolescents is addressed in the applicable section below.

Establishing an accurate diagnosis of gender dysphoria is important to help ensure that the procedures requested are appropriate to the individual's medical needs. As noted above, a diagnosis of gender dysphoria using DSM-5-TR criteria is considered in accordance with generally accepted standards of medical practice. Additionally, assessment should consider and exclude the likelihood that an individual's gender-related symptoms are the result of other causes that are unlikely to respond to gender affirming treatment, including psychosis, neurodiversity, and/or suppressed homosexuality. Recent scientific evidence has pointed to other important factors that may impact gender identity decisions, including peer interactions and exposure to social and other media. Given the complexity of the evaluation process, a multidisciplinary approach to the evaluation and management of an individual seeking gender affirming surgical treatment is considered in accordance with generally accepted standards of medical practice.

Management of co-morbid psychological conditions, including depression or anxiety, as well as self-harm, can have a significant impact on the successful outcome of gender affirming surgical procedures (particularly when the primary indication for surgery is psychological distress or incongruity). Similarly, adequate control of co-morbid medical conditions, such as endocrine or autoimmune disorders, is important to increase the likelihood of successful surgical and psychological outcomes.

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Gender Affirming Surgery

Policy # 00643

Original Effective Date: 12/19/2018

Current Effective Date: 10/14/2024

The WPATH SOC8 provides the following recommendations below for the treatment of adults requesting surgical treatment for gender dysphoria, which are conceptually aligned with criteria provided above in the Clinical Indications section.

For Adults: The following recommendations are made regarding the requirements for gender-affirming medical and surgical treatment (all should be met):

5.3- We recommend health care professionals assessing transgender and gender diverse adults for gender-affirming medical and surgical treatment:

5.3.a- Only recommend gender-affirming medical treatment requested by a TGD person when the experience of gender incongruence is marked and sustained.

5.3.b- Ensure fulfillment of diagnostic criteria prior to initiating gender-affirming treatments in regions where a diagnosis is necessary to access health care.

5.3.c- Identify and exclude other possible causes of apparent gender incongruence prior to the initiation of gender-affirming treatments.

5.3.d- Ensure that any mental health conditions that could negatively impact the outcome of gender-affirming medical treatments are assessed, with risks and benefits discussed, before a decision is made regarding treatment.

5.3.e- Ensure any physical health conditions that could negatively impact the outcome of gender-affirming medical treatments are assessed, with risks and benefits discussed, before a decision is made regarding treatment.

5.3.f- Assess the capacity to consent for the specific physical treatment prior to the initiation of this treatment.

5.3.g- Assess the capacity of the gender diverse and transgender adult to understand the effect of gender-affirming treatment on reproduction and explore reproductive options with the individual prior to the initiation of gender-affirming treatment.

5.4- We suggest, as part of the assessment for gender-affirming hormonal or surgical treatment, professionals who have competencies in the assessment of transgender and gender diverse people wishing gender-related medical treatment consider the role of social transition together with the individual.

5.5- We recommend transgender and gender diverse adults who fulfill the criteria for gender-affirming medical and surgical treatment require a single opinion for the initiation of this treatment from a professional who has competencies in the assessment of transgender and gender diverse people wishing gender-related medical and surgical treatment.

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Gender Affirming Surgery

Policy # 00643

Original Effective Date: 12/19/2018

Current Effective Date: 10/14/2024

5.6- We suggest health care professionals assessing transgender and gender diverse people seeking gonadectomy consider a minimum of 6 months of hormone therapy as appropriate to the TGD person's gender goals before the TGD person undergoes irreversible surgical intervention (unless hormones are not clinically indicated for the individual).

5.7- We recommend health care professionals assessing adults who wish to detransition and seek gender-related hormone intervention, surgical intervention, or both, utilize a comprehensive multidisciplinary assessment that will include additional viewpoints from experienced health care professional in transgender health and that considers, together with the individual, the role of social transition as part of the assessment process.

Criteria for surgery

- a. Gender incongruence is marked and sustained;
- b. Meets diagnostic criteria for gender incongruence prior to gender-affirming surgical intervention in regions where a diagnosis is necessary to access health care;
- c. Demonstrates capacity to consent for the specific gender-affirming surgical intervention;
- d. Understands the effect of gender-affirming surgical intervention on reproduction and they have explored reproductive options;
- e. Other possible causes of apparent gender incongruence have been identified and excluded;
- f. Mental health and physical conditions that could negatively impact the outcome of gender-affirming surgical intervention have been assessed, with risks and benefits have been discussed;
- g. Stable on their gender affirming hormonal treatment regime (which may include at least 6 months of hormone treatment or a longer period if required to achieve the desired surgical result, unless hormone therapy is either not desired or is medically contraindicated).*

*These were graded as suggested criteria

The WPATH SOC8 also include the following recommendations that they state for adults and adolescents:

13.2- We recommend surgeons assess transgender and gender diverse people for risk factors associated with breast cancer prior to breast augmentation or mastectomy.

13.3- We recommend surgeons inform transgender and gender diverse people undergoing gender-affirming surgical procedures about aftercare requirements, travel and accommodations, and the importance of postoperative follow-up during the preoperative process.

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Gender Affirming Surgery

Policy # 00643

Original Effective Date: 12/19/2018

Current Effective Date: 10/14/2024

13.4- We recommend surgeons confirm reproductive options have been discussed prior to gonadectomy in transgender and gender diverse people.

13.5- We suggest surgeons consider offering gonadectomy to eligible* transgender and gender diverse adults when there is evidence they have tolerated a minimum of 6 months of hormone therapy (unless hormone replacement therapy or gonadal suppression is not clinically indicated or the procedure is inconsistent with the patient's desires, goals, or expressions of individual gender identity).

13.6- We suggest health care professionals consider gender-affirming genital procedures for eligible* transgender and gender diverse adults seeking these interventions when there is evidence the individual has been stable on their current treatment regime (which may include at least 6 months of hormone treatment or a longer period if required to achieve the desired surgical result, unless hormone therapy is either not desired or is medically contraindicated).

13.7- We recommend surgeons consider gender-affirming surgical interventions for eligible* transgender and gender diverse adolescents when there is evidence a multidisciplinary approach that includes mental health and medical professionals has been involved in the decision-making process.

13.8- We recommend surgeons consult a comprehensive, multidisciplinary team of professionals in the field of transgender health when eligible* transgender and gender diverse people request individually customized (previously termed “non-standard”) surgeries as part of a gender-affirming surgical intervention.

13.9- We suggest surgeons caring for transgender men and gender diverse people who have undergone metoidioplasty/phalloplasty encourage lifelong urological follow-up.

13.10- We recommend surgeons caring for transgender women and gender diverse people who have undergone vaginoplasty encourage follow-up with their primary surgeon, primary care physician, or gynecologist.

13.11- We recommend patients who regret their gender-related surgical intervention be managed by an expert multidisciplinary team.

Criteria in the Coverage sections above that are procedure-specific are addressed below.

Chronicity/Timing of Surgical Procedures

Procedures for the chest, groin, and reproductive organs may not need to be done in conjunction with other procedures. Additionally, individuals undergoing top surgery do not need to subsequently undergo bottom surgery, or vice versa. The selection of appropriate procedures should be based on

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Gender Affirming Surgery

Policy # 00643

Original Effective Date: 12/19/2018

Current Effective Date: 10/14/2024

the needs of the individual as required for treatment for gender dysphoria. Furthermore, some surgical procedures may be done in stages with significant time delays between staged procedures. For purposes of this document, these series of procedures should be considered as a single procedure.

Gender Affirming Pelvic and Gonadal Procedures

Procedures addressing pelvic and gonadal anatomy (for example; hysterectomy, orchiectomy, ovariectomy, or salpingo-oophorectomy) in individuals with gender dysphoria are conducted to achieve the experienced physical anatomy and function aligning with the individual's experienced gender. Gender affirming pelvic and gonadal procedures have been shown in many studies to provide significant functional improvement in multiple areas (Almazan, 2021; Becker, 2018; Butler, 2019; Cardoso da Silva, 2016; Castellano, 2015; De Cuypere, 2005; de Vries, 2014; Djordjevic, 2009; Guss, 2015; Hage, 2006; Jellestad, 2018; Lawrence, 2006; Miller, 2019; Murad, 2010; Olson-Kennedy, 2018; Owen-Smith, 2018; Papadopulos, 2015; Simbar, 2018; Terrier, 2014; Tucker, 2018; van de Grift, 2017; Weigert, 2013; Wernick, 2019; Wierckx, 2011). These improvements include gender dysphoria-related symptoms such as psychological distress, depression, anxiety, and acceptance of the individual's body. Additionally, the available literature also demonstrates significant benefits related to quality of life and overall well-being.

The medical necessity criteria above for pelvic and gonadal procedures are based on several sources, including the WPATH SOC8, published peer-reviewed studies, and expert opinion. Gonadal and pelvic gender affirming surgical procedures present significant medical and psychological risks, and the results are irreversible (Djordjevic, 2016). The risk of these procedures should be discussed with any individual seeking gonadal and pelvic gender affirming surgical procedures.

Gender Affirming Genital Procedures

Gender affirming surgical procedures addressing genital anatomy (for example, clitoroplasty, labiaplasty, metoidioplasty, penectomy, phalloplasty, scrotoplasty, urethroplasty, vaginectomy, vaginoplasty/colovaginoplasty/coloproctostomy, or placement of penile or testicular prostheses) involve complex surgical techniques and present significant risk of surgical and medical complications. Before an individual undergoes these types of procedures, a thorough, multidisciplinary decision-making process should be utilized, one that involves adequate attempts at optimal hormonal therapy as well as successful completion of real-life experience in the experienced gender of the individual.

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Gender Affirming Surgery

Policy # 00643

Original Effective Date: 12/19/2018

Current Effective Date: 10/14/2024

Published peer-reviewed studies have shown that hormonal and psychological therapy and real-life experience living as the other gender, as well as social support and acceptance by peer and family groups, improve psychological outcomes in individuals undergoing gender affirming surgery (Eldh, 1997; Landen, 1998). Monstrey (2001) described the importance of close cooperation between the medical and behavioral specialties required for proper treatment of individuals with gender dysphoria who wish to undergo gender affirming surgery. Similar findings were reported earlier by Schlatterer (1996). One study of 188 subjects undergoing gender affirming surgery found that dissatisfaction with surgery was highly associated with sexual preference, psychological comorbidity, and poor pre-operative body image and satisfaction (Smith, 2005).

Hair removal Procedures

In many instances, the creation of a neovagina or a urethra for a neopenis requires an autologous skin graft from the forearm or thigh. Such skin may have hair present, which will impair the successful function of the newly constructed organ if not permanently removed. Pre-operative permanent hair removal treatments to these areas may be warranted to prevent post-operative complications.

Gender Affirming Chest Surgery:

The evidence addressing gender affirming chest surgery for the treatment of gender dysphoria supports a consistent association between surgery and satisfaction with breast appearance, psychological and sexual well-being, and body image and attractiveness; however, evidence supporting improvements in functional outcomes (for example, quality of life, gender dysphoria symptoms, or sequelae of severe illness, including crisis visits, suicide attempts, etc.) is less clear (Almazan, 2021; Becker, 2018; Miller, 2019; Olson-Kennedy, 2018; Weigert, 2013). Criteria for chest surgery are generally consistent with other gender affirming surgical procedures, including requirements related to age, capacity to consent, diagnosis of gender dysphoria, and reasonably well controlled concomitant physical and mental health conditions.

Criteria requiring hormone therapy for individuals assigned as male at birth (unless there is a medical contraindication or documented intolerance) aims to allow the development of at least some breast tissue prior to the desired surgery. As noted above in the section addressing GAHT, the use of hormone therapy has been shown to lead to breast development within the first 12 months, although development may continue through 2-3 years (De Blok, 2020a). Published studies have reported that

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Gender Affirming Surgery

Policy # 00643

Original Effective Date: 12/19/2018

Current Effective Date: 10/14/2024

final breast size varies significantly, anywhere from no growth to a C-cup, although the average individual achieves an A-cup in size.

A prospective case-control study published by Ascha in 2022 investigated the impact of gender affirming mastectomy procedures in a population of transmasculine or nonbinary adolescents and young adults aged between 13 and 24 years (mean 18.6 years). The study involved 36 subjects who underwent gender affirming mastectomy using the surgeon's procedure of choice. An additional 34 subjects seeking medical treatment for gender dysphoria who did not seek chest surgery were used as controls. This group was selected on the basis of age and duration of hormone therapy (± 1 year for both) to match the active treatment subjects. The study followed all subjects for 3 months, with 6 surgical group and 5 control group subjects lost to follow-up (15%). Subjects were predominantly white (89%), identified as transgender (84%), and were receiving testosterone therapy (96%). No significant differences between groups were reported with regard to baseline characteristics. Subjects lost to follow-up had significantly higher median scores on the Chest Dysphoria (CDM) tool and Body Image Scale (BIS), indicating a higher degree of chest-related dysphoria. The authors conducted an inverse probability of treatment weighting (IPTW) model analysis to estimate the association of the surgical procedure with outcomes. The mean significant difference in CDM score from baseline to 3 months for the surgical group was -28.12 vs. -0.52 in the control group subjects. The weighted model results indicated an estimated -25.58 difference between groups, suggesting significant improvement in the surgical group vs. controls. The IPTW model results for Transgender Congruence Scale (TCS) found similar results, indicating a 7.78 point increase in TCS scores between groups in favor of the surgical group. For BIS results, the IPTW model estimated a 7.20 improvement difference between groups, again in favor of the surgery group, indicating improved body satisfaction in the surgical group vs. the controls. This study is one of very few investigating the impact of gender affirming mastectomy in adolescents and young adults. While the results are promising, several issues should be noted. Firstly, it is unclear whether the control group represents a valid comparison group. Secondly, the results of the study may not be generalizable to younger (adolescent) individuals, given that majority of individuals enrolled in the study were 18 years of age and older (and most were between 16 and 21 years of age). Finally, a three month follow-up time may not be sufficient to assess outcomes relevant to the procedure in question or the condition being treated. Additional data from larger, well designed and conducted trials will continue to shed light on the potential benefits and risks of gender affirming mastectomy procedures in adolescents and young adults.

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Gender Affirming Surgery

Policy # 00643

Original Effective Date: 12/19/2018

Current Effective Date: 10/14/2024

While the WPATH SOC8 recommends only 6 months of GAHT, the international nature of the document should be considered, and that the use of 12 months of GAHT in the U.S. clinical setting is not unreasonable or unattainable.

Furthermore, significant variation in chest anatomy exists amongst cis-gendered individuals. Each individual considering gender affirming chest procedures should be assessed carefully, and significant variation from normal appearance for the experienced gender should be a considered factor in the decision-making process.

Gender Affirming Voice Modification Surgery

Some individuals with gender dysphoria may be dissatisfied with the pitch or other aspects of their voice, which may be considered not in alignment with their experienced gender. In many such cases the use of voice therapy has been shown to provide significant benefits. Additionally, for female-to-male (FtM) individuals, the use of testosterone GAHT alone has been demonstrated to provide the desired results. Conversely, for male-to-female (MtF) individuals, the use of estrogen GAHT has not been shown to provide significant benefits. Use of both voice therapy and GAHT should be considered as first-line approaches for individuals considering gender affirming voice modification surgery. When neither voice therapy nor GAHT are capable of providing the desirable results, gender affirming voice modification surgery may be warranted. It should be noted that the surgical approach poses significant potential risks, including surgical complications, undesired pitch, dysphonia, weak voice, restricted speaking range, hoarseness, and vocal instability.

The WPATH SOC8 addresses gender affirming voice modification and provides the following recommendations:

14.3- We recommend health care professionals in transgender health working with transgender and gender diverse people who are dissatisfied with their voice or communication consider offering a referral to voice and communication specialists for voice-related support, assessment, and training.

14.4- We recommend health care professionals consider working with transgender and gender diverse people who are considering undergoing voice surgery consider offering a referral to a voice and communication specialist who can provide pre- and/or postoperative support.

14.5- We recommend health care professionals in transgender health inform transgender and gender diverse people commencing testosterone therapy of the potential and variable effects of this treatment on voice and communication

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Gender Affirming Surgery

Policy # 00643

Original Effective Date: 12/19/2018

Current Effective Date: 10/14/2024

They additionally state:

Estrogen treatment in TGD people has not been associated with measurable voice changes (Mészáros et al., 2005), while testosterone treatment in TGD people has been found to result in both desired and undesired changes in gender and function-related aspects of voice production (Azul, 2015; Azul et al., 2017, 2018, 2020; Azul & Neuschaefer-Rube, 2019; Cosyns et al., 2014; Damrose, 2008; Deuster, Di Vincenzo et al., 2016; Deuster, Matulat et al. 2016; Hancock et al., 2017; Irwig et al., 2017; Nygren et al., 2016; Van Borsel et al., 2000; Yanagi et al., 2015; Ziegler et al., 2018).

WPATH notes that voice surgery to obtain a deeper voice in individuals desiring body masculinization is rare but may be recommended in some cases, such as when hormone therapy has been ineffective.

Published data evaluating gender affirming voice modification surgery is limited to postoperative satisfaction and vocal outcomes; functional outcomes (for example, quality of life, gender dysphoria symptoms, or sequelae of severe illness, including crisis visits, suicide attempts, etc.) have not been specifically assessed (Kim, 2020).

Gender Affirming Facial Surgery

The published data regarding gender affirming facial surgery generally support associations between surgery and likelihood of observers identifying an individual by their experienced gender; however, evidence supporting improvements in functional outcomes (for example, quality of life, gender dysphoria symptoms, or sequelae of severe illness, including crisis visits, suicide attempts, etc.) is less clear (Ainsworth, 2010; Cohen, 2018; Fisher, 2020; Morrison, 2020). Available data demonstrates that the long-term use of hormone therapy does quantifiably femininize or masculinize facial features, thus extended use of hormone therapy prior to facial feminization may be warranted in some circumstances (Tebbens, 2019).

In addition to providing general recommendations related to gender affirming surgical procedures, WPATH SOC8 provides specific criteria for the use of gender affirming facial feminization procedures.

Individuals with gender dysphoria who undergo gender affirming procedures may seek additional procedures to further alter their facial appearance when existing facial appearance demonstrates

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Gender Affirming Surgery

Policy # 00643

Original Effective Date: 12/19/2018

Current Effective Date: 10/14/2024

significant variation from normal appearance for the experienced gender. Gender affirming facial surgery may be a single procedure, or a combination or series of procedures. Commonly utilized procedures may include the following:

- Cheek reduction/enhancement
- Chin reduction/enhancement
- Facial bone reconstruction
- Facial implants
- Hair line advancement and/or hair transplant
- Jaw reduction (jaw contouring)
- Lip reduction/enhancement
- Lipofilling/collagen injections
- Nose implants
- Orbital procedures
- Rhinoplasty
- Thyroid cartilage reduction (chondrolaryngoplasty)

Other less common procedures listed by WPATH SOC8, such as blepharoplasty, liposuction, brow lift, reduction, or enhancement, may be used to alter facial appearance, when existing facial appearance demonstrates significant variation from normal appearance for the experienced gender.

Gender Affirming Chest Surgery in Individuals Under the Age of 18

Further consideration may be given for a gender affirming chest procedure in select adolescent individuals between the beginning of puberty through 17 years of age. Extenuating circumstances should be carefully considered, such as the level of maturity of the individual, duration and severity of dysphoric symptoms, coexisting medical and mental health issues, and other factors, which should be carefully documented and considered in consultation with a provider with experience treating adolescents with gender dysphoria.

The WPATH SOC8 provides the following surgical criteria for adolescent individuals:

- a. Gender diversity/incongruence is marked and sustained over time;
- b. Meets the diagnostic criteria of gender incongruence in situations where a diagnosis is necessary to access health care;

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Gender Affirming Surgery

Policy # 00643

Original Effective Date: 12/19/2018

Current Effective Date: 10/14/2024

- c. Demonstrates the emotional and cognitive maturity required to provide informed consent/assent for the treatment;
- d. Mental health concerns (if any) that may interfere with diagnostic clarity, capacity to consent, and gender-affirming medical treatments have been addressed; sufficiently so that gender-affirming medical treatment can be provided optimally.
- e. Informed of the reproductive effects, including the potential loss of fertility and the available options to preserve fertility;
- f. At least 12 months of gender-affirming hormone therapy or longer, if required, to achieve the desired surgical result for gender-affirming procedures, including breast augmentation, orchiectomy, vaginoplasty, hysterectomy, phalloplasty, metoidioplasty, and facial surgery as part of gender-affirming treatment unless hormone therapy is either not desired or is medically contraindicated.

Furthermore, the WPATH SOC8 provides the following recommendations for adolescents seeking surgical care:

The following recommendations are made regarding the requirements for gender-affirming medical and surgical treatment (All of them must be met):

6.12- We recommend health care professionals assessing transgender and gender diverse adolescents only recommend gender-affirming medical or surgical treatments requested by the patient when:

6.12.a- The adolescent meets the diagnostic criteria of gender incongruence as per the ICD-11 in situations where a diagnosis is necessary to access health care. In countries that have not implemented the latest ICD, other taxonomies may be used although efforts should be undertaken to utilize the latest ICD as soon as practicable.

6.12.b- The experience of gender diversity/incongruence is marked and sustained over time.

6.12.c- The adolescent demonstrates the emotional and cognitive maturity required to provide informed consent/assent for the treatment.

6.12.d- The adolescent's mental health concerns (if any) that may interfere with diagnostic clarity, capacity to consent, and gender-affirming medical treatments have been addressed.

6.12.e- The adolescent has been informed of the reproductive effects, including the potential loss of fertility and the available options to preserve fertility, and these have been discussed in the context of the adolescent's stage of pubertal development.

6.12.f- The adolescent has reached Tanner stage 2 of puberty for pubertal suppression to be initiated.

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Gender Affirming Surgery

Policy # 00643

Original Effective Date: 12/19/2018

Current Effective Date: 10/14/2024

6.12.g- The adolescent had at least 12 months of gender-affirming hormone therapy or longer, if required, to achieve the desired surgical result for gender-affirming procedures, including breast augmentation, orchiectomy, vaginoplasty, hysterectomy, phalloplasty, metoidioplasty, and facial surgery as part of gender-affirming treatment unless hormone therapy is either not desired or is medically contraindicated.

These criteria are provided to help ensure that use of surgical procedures in the treatment of adolescent individuals with gender dysphoria is conducted in a careful, thoughtful manner, taking into consideration multiple factors, including confirmation of the diagnosis of gender incongruence that is “sustained and marked”. This is a critical step in the assessment process, given that permanent, irreversible treatment actions are being considered. The WPATH SOC8 addresses this by stating, “Given potential shifts in gender-related experiences and needs during adolescence, it is important to establish the young person has experienced several years of persistent gender diversity/incongruence prior to initiating less reversible treatments such as gender-affirming hormones or surgeries.” It should be emphasized that WPATH SOC8 states the condition should be present for “*several years*” to establish the incongruity is “sustained”.

Confirmation of a diagnosis is important. Gender incongruity may represent the clinical presentation of multiple psychological conditions and careful diagnostic assessment is vital to accurate identification of gender dysphoria symptoms that are likely to respond to gender affirming surgery. Furthermore, as is noted in the DSM-5-TR, “Given the increased openness of gender-diverse expressions by individuals across the entire range of the transgender spectrum, it is important that the clinical diagnosis be limited to those individuals whose distress and impairment meet specified criteria.”

Possession of “adequate emotional and cognitive maturity required to perform informed consent/assent” is critical to help ensure an individual’s capacity to fully understand the short- and long-term consequences of any gender affirming surgical procedure. The capacity for adequate maturity may evolve over time with the development of physical and mental changes, beginning with puberty. These attributes may be challenging to assess, and a multidisciplinary approach to evaluation and treatment is strongly recommended. The evaluation process should involve professionals who are adequately trained and experienced in working with adolescent individuals with potential gender dysphoria, and that they work closely with the individual and their parent(s) or legal guardians.

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Gender Affirming Surgery

Policy # 00643

Original Effective Date: 12/19/2018

Current Effective Date: 10/14/2024

As discussed above, the use of GAHT may be an important factor in the long-term success of some gender affirming surgical procedures, including some chest procedures. Careful consideration should be taken to allow for the maximal therapeutic effects of GAHT to be established prior to any surgical procedures. The WPATH SOC8 states that a minimum of 12 months of GAHT “to achieve the desired surgical result for gender-affirming procedures, including breast augmentation” may be reasonable.

While WPATH SOC8 provides recommendations in support of surgical procedures other than chest surgery for adolescents, significant controversy surrounds the topic, particularly for gonad and genital procedures. While chest surgery is not fully reversible, other significant risks and complex long-term sequelae accompany gonad and genital surgery, including serious surgical complications and outcomes related to psychological, urinary, sexual, and fertility function. Insufficient consensus has been established to consider gonad and genital surgery for adolescents with gender dysphoria in accordance with generally accepted standards of medical practice.

Referral Letters

An independent assessment of an individual by a qualified mental health professional is considered standard of care before an individual undergoes a gender affirming surgical procedure.

The WPATH SOC8 recommends the following regarding referral letters in support of gender affirming surgery in adults:

5.5- We recommend transgender and gender diverse adults who fulfill the criteria for gender-affirming medical and surgical treatment require a single opinion for the initiation of this treatment from a professional who has competencies in the assessment of transgender and gender diverse people wishing gender-related medical and surgical treatment.

They further supply the following criteria for surgical treatment of adults and adolescents, "Health care professionals assessing transgender and gender diverse adults seeking gender-affirming treatment should liaise with professionals from different disciplines within the field of trans health for consultation and referral, if required*" and "If written documentation or a letter is required to recommend gender affirming medical and surgical treatment (GAMST), only one letter of assessment from a health care professional who has competencies in the assessment of transgender and gender diverse people is needed"

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Gender Affirming Surgery

Policy # 00643

Original Effective Date: 12/19/2018

Current Effective Date: 10/14/2024

The WPATH SOC8 includes the following recommendations regarding required opinions prior to gender affirming surgical procedures:

5.5- We recommend transgender and gender diverse adults who fulfill the criteria for gender-affirming medical and surgical treatment require a single opinion for the initiation of this treatment from a professional who has competencies in the assessment of transgender and gender diverse people wishing gender-related medical and surgical treatment.

6.9- We recommend health care professionals involve relevant disciplines, including mental health and medical professionals, to reach a decision about whether puberty suppression, hormone initiation, or gender-related surgery for gender diverse and transgender adolescents are appropriate and remain indicated throughout the course of treatment until the transition is made to adult care.

13.7- We recommend surgeons consider gender-affirming surgical interventions for eligible* transgender and gender diverse adolescents when there is evidence a multidisciplinary approach that includes mental health and medical professionals has been involved in the decision-making process.

13.8- We recommend surgeons consult a comprehensive, multidisciplinary team of professionals in the field of transgender health when eligible* transgender and gender diverse people request individually customized (previously termed “non-standard”) surgeries as part of a gender-affirming surgical intervention.

From these recommendations, it is clear that a multidisciplinary approach is preferred and multiple experienced and qualified providers should be involved in the decision-making process when a surgical intervention is under consideration. The requirement of more than one opinion is generally not considered overly burdensome in an advanced healthcare setting such as is found in the U.S.

In this guideline, only one letter is required for chest, facial, and voice gender affirming surgical procedures. However, given the potential surgical complications and long-term ramifications on psychological, physical, fertility, and social function related to gonad and genital gender affirming surgical procedures, it is considered clinically appropriate to require the opinion of two experts involved in the treatment of individuals with gender dysphoria who are considering these interventions.

Additionally, the WPATH SOC8 provides the following recommendations regarding the credentials for mental health professionals who work with adults presenting with gender dysphoria:

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Gender Affirming Surgery

Policy # 00643

Original Effective Date: 12/19/2018

Current Effective Date: 10/14/2024

5.1- We recommend health care professionals assessing transgender and gender diverse adults for physical treatments:

5.1.a- Are licensed by their statutory body and hold, at a minimum, a master's degree or equivalent training in a clinical field relevant to this role and granted by a nationally accredited statutory institution.

5.1.b- For countries requiring a diagnosis for access to care, the health care professional should be competent using the latest edition of the World Health Organization's International Classification of Diseases (ICD) for diagnosis. In countries that have not implemented the latest ICD, other taxonomies may be used; efforts should be undertaken to utilize the latest ICD as soon as practicable.

5.1.c- Are able to identify co-existing mental health or other psychosocial concerns and distinguish these from gender dysphoria, incongruence, and diversity.

5.1.d- Are able to assess capacity to consent for treatment.

5.1.e- Have experience or be qualified to assess clinical aspects of gender dysphoria, incongruence, and diversity.

5.1.f- Undergo continuing education in health care relating to gender dysphoria, incongruence, and diversity.

5.2- We suggest health care professionals assessing transgender and gender diverse adults seeking gender-affirming treatment liaise with professionals from different disciplines within the field of transgender health for consultation and referral, if required.

Procedures to Address Postoperative Complications of Gender Affirming Surgery and Reversal Surgery

Procedures to address postoperative complications of a prior gender affirming surgery (for example, scarring, stenosis, infection, etc.) are not considered separate gender affirming surgery procedures and are not addressed in this document.

Reversal Procedures

Reversal of a prior gender affirming surgery procedure is rare and is considered gender affirming surgery. According to the literature on this issue, the predominant factor in requests for reversals are regret, which has been further associated with age greater than 30 at first surgery, personality disorders, early loss of both parents, social instability, preoperative male heterosexual sexual orientation, degree of social support, secondary transsexualism, early decision to undergo surgery

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Gender Affirming Surgery

Policy # 00643

Original Effective Date: 12/19/2018

Current Effective Date: 10/14/2024

and dissatisfaction with surgical results (Blanchard, 1989; Landén, 1998; Lawrence, 2003; Lindemalm, 1986 and 1987; Olsson, 2006).

Djordjevic (2016) reported on the outcomes of surgical reversal surgery in MtF individuals wishing to transition back to male. While the main focus of this paper is related to surgical outcomes, the authors reported on characteristics of the participating subjects and contributing factors to the reversal decisions. The seven subjects had an absence of “real-life experience” prior to surgery, absence or inappropriate hormonal treatment, recommendations by inexperienced professionals, and insufficient hormonal therapy and medical follow-up. Furthermore, they failed to fulfill the complete diagnostic criteria for gender dysphoria. The authors concluded that the main factor contributing to regret was absence of proper pretreatment assessment. In their reversal protocol, each subject was required to have recommendations from three well-known WPATH psychiatrists prior to reversal procedures.

The available evidence indicates the importance of thorough preoperative physical and psychological evaluation and treatment as being a critical factor in postoperative success. As noted above, these aspects of the treatment process are critical to sufficiently prepare an individual for the social, physical, and mental ramifications of the decision to undergo gender affirming surgery.

The clinical evidence addressing the satisfaction and quality of life following gender affirming surgery is limited, and the reported findings are mixed (Cardoso da Silva, 2016; Castellano, 2015). It is important that proper and thorough pre-operative work-up and preparation be conducted in individuals considering such life-altering procedures. Additionally, long-term post-operative follow-up, including availability of mental health services, may also contribute to satisfaction with surgical results.

Detransitioning

Detransitioning is a term used to refer to individuals who return to the gender assigned at birth following a process of transition to a gender other than the one assigned at birth. Regret may or may not be a component of the detransition process. A small number of published studies involving survey methodology and self-reported data have described detransition cases, the characteristics of the individuals involved, and the factors influencing both. The vast majority of individuals involved in these reports have not undergone gender affirming surgery or undergone reversal procedures.

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Gender Affirming Surgery

Policy # 00643

Original Effective Date: 12/19/2018

Current Effective Date: 10/14/2024

Turban (2021) reported on a secondary analysis of data derived from the United States Transgender Survey (USTS), a cross-sectional nonprobability sample conducted by the National Center for Transgender People, a non-governmental advocacy organization. The USTS survey includes data from 27,715 transgender respondents aged 18 years or older located in the U.S., its territories, and military. A total of 2242 respondents indicated a history of detransition, which the survey defined as “a process through which a person discontinues some or all aspects of gender affirmation.” Roughly half of the respondents (55.1%) indicated they had received gender affirming hormone therapy, and 16.5% had obtained one or more gender affirming surgical procedures. The authors reported detransition was significantly associated with male sex assigned at birth, non-binary gender, having an unsupportive family, and never having undergone hormone therapy or gender affirming surgery ($p < 0.001$ for all). Additionally, 82.5% of respondents cited at least one external factor leading to detransition, including pressure from parents and family, community, or employer. A total of 15.9% cited an internal factor in their decision to detransition, including fluctuations in identity or desire to pursue treatment, and difficulty with the process.

Vandenbussche (2021) reported the results of a 24-multiple choice question online questionnaire involving 237 respondents who positively answered ‘yes’ to the question, “Did you transition medically and/or surgically and then stop?” Respondents were predominantly female (92%). More than half of respondents were from the U.S. (51%), 32% were from Europe, 6% were from Canada, and the remaining were from Australia (5%). Medical and social transition had been conducted by 65% of respondents and 31% had transitioned only socially. Over half (51%) began socially transitioning prior to the age of 18, and 25% began medical transition prior to that age as well. The average duration of transition was 4.71 years. Detransition prior to the age of 18 was reported in 14% of respondents and the average age of detransition was 22.88 years. A total of 45% of respondents indicated that they felt they had not been properly informed of the health implications of the available interventions before undergoing them. Significantly, 70% of respondents reported that their detransition was the result of their realizing their gender dysphoria was related to other issues and 50% reported that transitioning did not help their dysphoria. Other reasons provided for detransitioning were alternatives were found that helped with dysphoria (45%), unhappiness with social transition (44%), and change in political views (43%). In contradiction to the results reported by Turban et al., a lack of social support, financial concerns, and discrimination were at the bottom of reasons listed for detransition (13%, 12%, and 10%, respectively).

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Gender Affirming Surgery

Policy # 00643

Original Effective Date: 12/19/2018

Current Effective Date: 10/14/2024

In 2021 Littman reported on a survey study of 100 subjects responding to a 115-question online survey who had transitioned and detransitioned medically, surgically, or both. Subjects were recruited via social media platforms. Additional referrals for subjects were sought via professional listservs for WPATH members and sex researchers. Detransition for the purposes of this study was defined as “the act of stopping or reversing a gender transition”. A majority of subjects reported early onset gender dysphoria (56%). The sample population was overwhelmingly white (90%) and female (69%). When asked for the reason behind their initial transition, 71% responded that they believed that transitioning was their only option to feel better. Most respondents (65%) believed that transitioning would eliminate or decrease their gender dysphoria symptoms, and 64% responded that they believed that transitioning would ‘allow them to become their true selves’. Most respondents reported that external factors encouraged them to transition, with online sources the most frequently cited (48%). More than a third (37.4%) felt pressured to transition. Pre-transition care was provided by a wide variety of sources, including gender clinics (44.4%), private practice providers (28%), group practices (26%), mental health clinics (13%). In line with what was previously reported by Turban, a majority of respondents (56.7%) reported feeling that the evaluation they received by their provider prior to their transition was not adequate, with 65% indicating that their provider did not evaluate if their desire to transition was due to trauma or a mental health condition. Only 27% reported that they felt their pre-treatment counseling was sufficiently accurate about the risks and benefits of the desired procedures. Nearly half (46%) indicated that they felt the pre-treatment counseling was overly positive about the benefits of transition and 26 reported that it was not ‘negative enough about the risks’. Chest surgery was the most frequently reported surgical procedure in FtM transitions (33.3%), Genital procedures were reported in 1.4% of FtM transition respondents and 16.1% of MtF transitions. Gender affirming hormone therapy was reported in 96% of subjects. Mean duration of transition was 3.9 years, with FtM transitions shorter than MtF transitions (3.2 vs. 5.4 years, $p=0.018$). The most frequently cited reason for detransitioning was that the respondent “became comfortable with their natal sex” (60%). Other frequently cited reasons included concerns about potential medical complications (49%), transition did not improve their mental health (42%), dissatisfaction with the results of transition (40%), and discovering something specific, such as trauma or mental health conditions were the cause of their dysphoria (38%). Contrary to Turban, external forces such as discrimination (23%), financial concerns (17%), and online sources (29%) were less prevalent reasons cited for detransitioning. Medical detransition by ceasing hormone therapy was done by 95% of respondents, while reversal procedures were sought by 9%. Retransition after detransition was reported in 3% of subjects. A majority (58%) of respondents stated that their dysphoria was related to trauma or a mental health condition, and 51% stated that transition delayed

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Gender Affirming Surgery

Policy # 00643

Original Effective Date: 12/19/2018

Current Effective Date: 10/14/2024

their receiving proper care for their underlying condition. Underlying internalized homophobia, difficulty accepting oneself as homosexual, was reported as the source of dysphoria in 23% of responses. At the end of the survey period, 61% of respondents had returned to their birth sex, with an additional 10% identifying with their birth sex and 24% identifying as non-binary or non-binary plus a second identification. A third of respondents (30%) had indicated that they wished they had never transitioned, while 11% were glad they had. Thirty-four percent said their transition was a necessary part of their journey and 21% said it had distracted from “what they should have been doing”. Finally, 79% of respondents reported some amount of regret, 49.5% reported strong regret, and 64.6% reported that they would not have chosen to transition had they known what they knew at the time of the survey.

The data surrounding detransitioning is limited, primarily derived from case series that may not represent the general population of individuals presenting with gender dysphoria; however, several important issues should be noted. First, in some individuals, symptoms of gender dysphoria may not be permanent. Second, a careful evaluation should be conducted to help ensure an accurate diagnosis, including assessment of influencing factors such as underlying mental illness, prior trauma, and unidentified homosexuality. Third, external influences such as online resources, family and peer groups may play a significant role in influencing the decision-making process of some individuals seeking care for gender dysphoria. Lastly, early and adequate education regarding the risks and benefits of gender dysphoria treatment should be offered to individuals seeking gender affirming treatment. Additional research is needed to understand the phenomenon of detransitioning, including its prevalence, and internal and external factors that play a role in the process, as well as how diagnostic and counseling support can be utilized to reduce harms, including unnecessary treatment, in individuals presenting with gender dysphoria symptoms.

Other Procedures

Additional surgeries have been proposed to improve the gender appropriate appearance of the individual. Such procedures are considered cosmetic under most member contracts regardless of claim of medical necessity, and when intended to change a physical appearance that would be considered within normal human anatomic variation or are primarily intended to preserve or improve appearance irrespective of gender-defining features.

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Gender Affirming Surgery

Policy # 00643

Original Effective Date: 12/19/2018

Current Effective Date: 10/14/2024

Such procedures may include the following:

- A. Blepharoplasty
- B. Breast augmentation
- C. Brow lift
- D. Face lift
- E. Facial bone reconstruction
- F. Facial implants
- G. Hair removal (for example, electrolysis or laser) and hairplasty
- H. Jaw reduction (jaw contouring)
- I. Lip reduction/enhancement
- J. Lipofilling/collagen injections
- K. Lipoplasty
- L. Liposuction
- M. Nose implants
- N. Pectoral implants
- O. Rhinoplasty
- P. Thyroid cartilage reduction (chondroplasty)
- Q. Voice modification surgery

Other procedures are not generally intended to address anatomy directly related to symptoms of gender dysphoria, including the following:

- A. Abdominoplasty
- B. Body contouring
- C. Gluteal implants

Children:

At this time no authoritative organization recommends the use of surgical procedures to treat gender dysphoria in children, defined in the WPATH SOC8 as individuals from birth through the start of puberty. This population has not yet completed the cognitive, emotional, psychological, and social growth needed to have the capacity to fully comprehend issues involved in pre-surgical decision making or to make informed decisions of such a serious nature. Furthermore, it is widely recognized that in this population gender trajectories cannot be predicted and may evolve over time.

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Gender Affirming Surgery

Policy # 00643

Original Effective Date: 12/19/2018

Current Effective Date: 10/14/2024

Non-Binary, Eunuch and Intersex Individuals

The surgical treatment of non-binary, eunuch and intersex individuals is not specifically addressed in this document; however, when a diagnosis of gender dysphoria been made, the criteria set forth in this document may apply.

Supplemental Information

Other Guidelines

In late 2017, the Endocrine Society released a clinical practice guideline for the endocrine treatment of gender-dysphoric/gender-incongruent persons (Hembree, 2017). This publication was co-sponsored by the American Association of Clinical Endocrinologists, the American Society of Andrology, the European Society for Pediatric Endocrinology, the European Society of Endocrinology, the Pediatric Endocrine Society, and WPATH. Among other recommendations this document includes the following:

- 2.1. We suggest that adolescents who meet diagnostic criteria for GD/gender incongruence, fulfill criteria for treatment, and are requesting treatment should initially undergo treatment to suppress pubertal development.
- 2.2. We suggest that clinicians begin pubertal hormone suppression after girls and boys first exhibit physical changes of puberty.
- 2.3. We recommend that, where indicated, GnRH analogues are used to suppress pubertal hormones.
- 2.4. In adolescents who request sex hormone treatment (given this is a partly irreversible treatment), we recommend initiating treatment using a gradually increasing dose schedule after a multidisciplinary team of medical and MHPs has confirmed the persistence of GD/gender incongruence and sufficient mental capacity to give informed consent, which most adolescents have by age 16 years.
- 2.5. We recognize that there may be compelling reasons to initiate sex hormone treatment prior to the age of 16 years in some adolescents with GD/gender incongruence, even though there are minimal published studies of gender-affirming hormone treatments administered before age 13.5 to 14 years. As with the care of adolescents ≥ 16 years of age, we recommend that an expert multidisciplinary team of medical and MHPs manage this treatment.
- 5.1. We recommend that a patient pursue genital gender-affirming surgery only after the MHP and the clinician responsible for endocrine transition therapy both agree that surgery is medically necessary and would benefit the patient's overall health and/or well-being.

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Gender Affirming Surgery

Policy # 00643

Original Effective Date: 12/19/2018

Current Effective Date: 10/14/2024

5.2. We advise that clinicians approve genital gender affirming surgery only after completion of at least 1 year of consistent and compliant hormone treatment unless hormone therapy is not desired or medically contraindicated. (Ungraded Good Practice Statement)

5.3. We advise that the clinician responsible for endocrine treatment and the primary care provider ensure appropriate medical clearance of transgender individuals for genital gender-affirming surgery and collaborate with the surgeon regarding hormone use during and after surgery. (Ungraded Good Practice Statement)

5.4. We recommend that clinicians refer hormone treated transgender individuals for genital surgery when: (1) the individual has had a satisfactory social role change, (2) the individual is satisfied about the hormonal effects, and (3) the individual desires definitive surgical changes.

5.5. We suggest that clinicians delay gender-affirming genital surgery involving gonadectomy and/or hysterectomy until the patient is at least 18 years old or legal age of majority in his or her country.

Note: “MHP” is the Endocrine Society’s abbreviation for “mental health professional”.

References

Peer Reviewed Publications:

1. Ainsworth TA, Spiegel JH. Quality of life of individuals with and without facial feminization surgery or gender reassignment surgery. *Qual Life Res.* 2010; 19(7):1019-24.
2. Almazan AN, Keuroghlian AS. Association between gender-affirming surgeries and mental health outcomes. *JAMA Surg.* 2021; 156(7):611-618.
3. Ascha M, Sasson DC, Sood R, et al. Top surgery and chest dysphoria among transmasculine and nonbinary adolescents and young adults. *JAMA Pediatr.* 2022; 176(11):1115-1122.
4. Becker I, Auer M, Barkmann C, Fuss J, et al. A cross-sectional multicenter study of multidimensional body image in adolescents and adults with gender dysphoria before and after transition-related medical interventions. *Arch Sex Behav.* 2018; 47(8):2335-2347.
5. Becking AG, Tuinzing DB, Hage JJ, Gooren LJ. Facial corrections in male to female transsexuals: a preliminary report on 16 patients. *J Oral Maxillofac Surg.* 1996; 54(4):413-418.
6. Blanchard R, Steiner BW, Clemmensen LH, Dickey R. Prediction of regrets in postoperative transsexuals. *Can J Psychiatry.* 1989; 34(1):43-45.
7. Bradley SJ, Zucker KJ. Gender identity disorder: a review of the past 10 years. *J Am Acad Child Adolesc Psychiatry.* 1997; 36(7):872-880.

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Gender Affirming Surgery

Policy # 00643

Original Effective Date: 12/19/2018

Current Effective Date: 10/14/2024

8. Butler RM, Horenstein A, Gitlin M, Testa RJ, et al. Social anxiety among transgender and gender nonconforming individuals: The role of gender-affirming medical interventions. *J Abnorm Psychol.* 2019; 128(1):25-31.
9. Capitán L, Simon D, Kaye K, Tenorio T. Facial feminization surgery: the forehead. *Surgical techniques and analysis of results. Plast Reconstr Surg.* 2014; 134(4):609-619.
10. Cardoso da Silva D, Schwarz K, Fontanari AM, et al. WHOQOL-100 before and after sex reassignment surgery in Brazilian male-to-female transsexual individuals. *J Sex Med.* 2016; 13(6):988-993.
11. Castellano E, Crespi C, Dell'Aquila C, et al. Quality of life and hormones after sex reassignment surgery. *J Endocrinol Invest.* 2015; 38(12):1373-1381.
12. Cohen MB, Insalaco LF, Tonn CR, Spiegel JH. Patient satisfaction after aesthetic chondrolaryngoplasty. *Plast Reconstr Surg Glob Open.* 2018; 6(10):e1877.
13. Cohen-Kettenis PT, Gooren LJ. Transsexualism: a review of etiology, diagnosis and treatment. *J Psychosom Res.* 1999; 46(4):315-333.
14. Coleman E, Radix AE, Bouman WP, et al. (2022). Standards of care for the Health of Transgender and Gender Diverse People, Version 8. *International Journal of Transgender Health.* 23:1, S1-S259. <https://www.tandfonline.com/doi/pdf/10.1080/26895269.2022.2100644>
15. Cristofari S, Bertrand B, Leuzzi S, et al Postoperative complications of male to female sex reassignment surgery: A 10-year French retrospective study. *Ann Chir Plast Esthet.* 2018. Pii: S0294-1260(18)30142-0.
16. de Blok CJM, Dijkman BAM, Wiepjes CM, et al. Sustained breast development and breast anthropometric changes in three years gender-affirming hormone treatment. *J Clin Endocrinol Metab.* 2021; 106(2):e782-e790.
17. de Blok CJM, Klaver M, Wiepjes CM, et al. Breast development in transwomen after 1 year of cross-sex hormone therapy: results of a prospective multicenter study. *J Clin Endocrinol Metab.* 2018; 103(2):532-538.
18. De Cuypere G, T'Sjoen G, Beerten R, et al. Sexual and physical health after sex reassignment surgery. *Arch Sex Behav.* 2005; 34(6):679-690.
19. de Vries AL, McGuire JK, Steensma TD, et al. Young adult psychological outcome after puberty suppression and gender reassignment. *Pediatrics.* 2014; 134(4):696-704.
20. Djordjevic ML, Bizic MR, Duisin D, et al. Reversal surgery in regretful male-to-female transsexuals after sex reassignment surgery. *J Sex Med.* 2016; 13(6):1000-1007.
21. Djordjevic ML, Stanojevic D, Bizic M, et al. Metoidioplasty as a single stage sex reassignment surgery in female transsexuals: Belgrade experience. *J Sex Med.* 2009; 6(5):1306-1313.

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Gender Affirming Surgery

Policy # 00643

Original Effective Date: 12/19/2018

Current Effective Date: 10/14/2024

22. Eldh J, Berg A, Gustafsson M. Long-term follow up after sex reassignment surgery. *Scand J Plast Reconstr Surg Hand Surg.* 1997; 31(1):39-45.
23. Fisher M, Lu SM, Chen K, et al. Facial feminization surgery changes perception of patient gender. *Aesthet Surg J.* 2020; 40(7):703-709.
24. Guss C, Shumer D, Katz-Wise SL. Transgender and gender nonconforming adolescent care: psychosocial and medical considerations. *Curr Opin Pediatr.* 2015; 27(4):421-426.
25. Hage JJ, van Turnhout AA. Long-term outcome of metaidoioplasty in 70 female-to-male transsexuals. *Ann Plast Surg.* 2006; 57(3):312-316
26. Hall R, Mitchell L, Sachdeva J. Access to care and frequency of detransition among a cohort discharged by a UK national adult gender identity clinic: retrospective case-note review. *BJPsych Open.* 2021; 7(6):e184.
27. Hepp U, Kraemer B, Schnyder U, et al. Psychiatric comorbidity in gender identity disorder. *J Psychosom Res.* 2005; 58(3):259-261.
28. Jellestad L, Jäggi T, Corbisiero S, et al. Quality of life in transitioned trans persons: a retrospective cross-sectional cohort study. *Biomed Res Int.* 2018; 2018:8684625.
29. Landén M, Wålinder J, Lambert G, Lundström B. Factors predictive of regret in sex reassignment. *Acta Psychiatri Scand.* 1998; 7(4):284-289.
30. Lawrence AA. Factors associated with satisfaction or regret following male-to-female sex reassignment surgery. *Arch Sex Behav.* 2003; 32(4):299-315.
31. Lawrence AA. Patient-reported complications and functional outcomes of male-to-female sex reassignment surgery. *Arch Sex Behav.* 2006; 35(6):717-727.
32. Lindemalm G, Körlin D, Uddenberg N. Long-term follow-up of "sex change" in 13 male-to-female transsexuals. *Arch Sex Behav.* 1986; 15(3):187-210.
33. Lindemalm G, Körlin D, Uddenberg N. Prognostic factors vs. outcome in male-to-female transsexualism. A follow-up study of 13 cases. *Acta Psychiatr Scand.* 1987; 75(3):268-274.
34. Littman L. Individuals treated for gender dysphoria with medical and/or surgical transition who subsequently detransitioned: a survey of 100 detransitioners. *Arch Sex Behav.* 2021; 50(8):3353-3369.
35. Mate-Kole C, Freschi M, Robin A. A controlled study of psychological and social change after surgical gender reassignment in selected male transsexuals. *Br J Psychiatry.* 1990; 157:261-264.
36. Midence K, Hargreaves I. Psychosocial adjustment in male-to-female transsexuals: an overview of the research evidence. *J Psychol.* 1997; 131(6):602-614.
37. Miller TJ, Wilson SC, Massie JP, et al. Breast augmentation in male-to-female transgender patients: Technical considerations and outcomes. *JPRAS Open.* 2019; 21:63-74.

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Gender Affirming Surgery

Policy # 00643

Original Effective Date: 12/19/2018

Current Effective Date: 10/14/2024

38. Monstrey S, Hoebeke P, Dhont M, et al. Surgical therapy in transsexual patients: a multi-disciplinary approach. *Acta Chir Belg.* 2001; 101(5):200-209.
39. Morrison SD, Capitán-Cañadas F, Sánchez-García A, et al. Prospective quality-of-life outcomes after facial feminization surgery: an international multicenter study. *Plast Reconstr Surg.* 2020; 145(6):1499-1509.
40. Murad MH, Elamin MB, Garcia MZ, et al. Hormonal therapy and sex reassignment: a systematic review and meta-analysis of quality of life and psychosocial outcomes. *Clin Endocrinol (Oxf).* 2010; 72(2):214-231.
41. Olson-Kennedy J, Warus J, Okonta V, et al. Chest reconstruction and chest dysphoria in transmasculine minors and young adults: comparisons of nonsurgical and postsurgical cohorts. *JAMA Pediatr.* 2018; 172(5):431-436.
42. Olsson SE, Möller A. Regret after sex reassignment surgery in a male-to-female transsexual: a long-term follow-up. *Arch Sex Behav.* 2006; 35(4):501-506.
43. Owen-Smith AA, Gerth J, Sineath RC, et al. association between gender confirmation treatments and perceived gender congruence, body image satisfaction, and mental health in a cohort of transgender individuals. *J Sex Med.* 2018; 15(4):591-600.
44. Papadopoulos NA, Zavlin D, Lellé JD, et al. Male-to-female sex reassignment surgery using the combined technique leads to increased quality of life in a prospective study. *Plast Reconstr Surg.* 2017; 140(2):286-294.
45. Ruppin U, Pfäfflin F. Long-term follow-up of adults with gender identity disorder. *Arch Sex Behav.* 2015; 44(5):1321-1329.
46. Schlatterer K, von Werder K, Stalla GK. Multistep treatment concept of transsexual patients. *Exp Clin Endocrinol Diabetes.* 1996; 104(6):413-419.
47. Selvaggi G, Ceulemans P, De Cuypere G, et al. Gender identity disorder: general overview and surgical treatment for vaginoplasty in male-to-female transsexuals. *Plast Reconstr Surg.* 2005; 116(6):135e-145e.
48. Simbar M, Nazarpour S, Mirzababaie M, et al. quality of life and body image of individuals with gender dysphoria. *J Sex Marital Ther.* 2018; 44(6):523-532.
49. Smith YL, Van Goozen SH, Kuiper AJ, Cohen-Kettenis PT. Sex reassignment: outcomes and predictors of treatment for adolescent and adult transsexuals. *Psychol Med.* 2005; 35(1):89-99.
50. Tebbens M, Nota NM, Liberton NPTJ, et al. Gender-affirming hormone treatment induces facial feminization in transwomen and masculinization in transmen: quantification by 3D scanning and patient-reported outcome measures. *J Sex Med.* 2019; 16(5):746-754.

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Gender Affirming Surgery

Policy # 00643

Original Effective Date: 12/19/2018

Current Effective Date: 10/14/2024

51. Terrier JÉ, Courtois F, Ruffion A, Morel Journal N. Surgical outcomes and patients' satisfaction with suprapubic phalloplasty. *J Sex Med.* 2014; 11(1):288-298.
52. Tucker RP, Testa RJ, Simpson TL, et al. Hormone therapy, gender affirmation surgery, and their association with recent suicidal ideation and depression symptoms in transgender veterans. *Psychol Med.* 2018; 48(14):2329-2336.
53. Turban JL, Loo SS, Almazan AN, Keuroghlian AS. Factors leading to "detransition" among transgender and gender diverse people in the United States: A mixed-methods analysis. *LGBT Health.* 2021; 8(4):273-280.
54. van de Grift TC, Elaut E, Cerwenka SC, et al. Effects of medical interventions on gender dysphoria and body image: a follow-up study. *Psychosom Med.* 2017; 79(7):815-823.
55. Vandebussche E. Detransition-related needs and support: a cross-sectional online survey. *J Homosex.* 2021 Apr 30:1-19. Epub ahead of print.
56. Weigert R, Frison E, Sessieq Q, et al. Patient satisfaction with breasts and psychosocial, sexual, and physical well-being after breast augmentation in male-to-female transsexuals. *Plast Reconstr Surg.* 2013; 132(6):1421-1429.
57. Wernick JA, Busa S, Matouk K, Nicholson J, Janssen A. A systematic review of the psychological benefits of gender-affirming surgery. *Urol Clin North Am.* 2019; 46(4):475-486.
58. Wierckx K, Van Caenegem E, Elaut E, et al. Quality of life and sexual health after sex reassignment surgery in transsexual men. *J Sex Med.* 2011; 8(12):3379-3388.
59. Yarbrough E, Kidd J, Parekh, R. (2017, Nov.). A Guide for Working With Transgender and Gender Nonconforming Patients: Gender Dysphoria Diagnosis. American Psychiatric Association. <https://www.psychiatry.org/psychiatrists/diversity/education/transgender-and-gender-nonconforming-patients/gender-dysphoria-diagnosis>

Government Agency, Medical Society, and Other Authoritative Publications:

1. American College of Obstetricians and Gynecologists' Committee on Gynecologic Practice; American College of Obstetricians and Gynecologists' Committee on Health Care for Underserved Women. Health care for transgender and gender diverse individuals: ACOG Committee Opinion, Number 823. *Obstet Gynecol.* 2021; 137(3):e75-e88.
2. American College of Obstetricians and Gynecology. Elective Female Genital Cosmetic Surgery: ACOG Committee Opinion, Number 795. Committee on Gynecologic Practice. *Obstet Gynecol.* 2020; 135(1):e36-e42.
3. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition Text Revision. February 2022. Washington, DC. Pages 511-520.

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Gender Affirming Surgery

Policy # 00643

Original Effective Date: 12/19/2018

Current Effective Date: 10/14/2024

4. Hembree WC, Cohen-Kettenis PT, Gooren L, et al. Endocrine treatment of gender-dysphoric/gender-incongruent persons: an Endocrine Society clinical practice guideline. *Endocr Pract.* 2017; 23(12):1437.
5. World Health Organization (WHO). International Classification of Diseases (ICD)-11 for Mortality and Morbidity Statistics (Version: 02/2022). Available at: <https://icd.who.int/browse11/1-m/en#/http://id.who.int/icd/entity/90875286>.
6. World Professional Association for Transgender Health (WPATH). Standards of care for the health of transgender and gender diverse people. 8th version. 2022. Available at: <https://www.wpath.org/soc8>.
7. World Professional Association for Transgender Health (WPATH). Standards of care for the health of transsexual, transgender, and gender nonconforming people. 7th version. 2012. Available at: <https://www.wpath.org/publications/soc>.
8. World Professional Association for Transgender Health (WPATH). Standards of Care for Gender Identity Disorders. 6th version. 2001 Feb.

Policy History

Original Effective Date: 12/19/2018

Current Effective Date: 10/14/2024

- 12/06/2018 Medical Policy Committee review
- 12/19/2018 Medical Policy Implementation Committee approval. New policy.
- 12/05/2019 Medical Policy Committee review
- 12/11/2019 Medical Policy Implementation Committee approval. Revised eligible for coverage criteria for bilateral mastectomy to require one referral letter. Added new notes addressing treatment of postoperative complications and reversal procedures.
- 01/17/2020 Coding update
- 05/07/2020 Medical Policy Committee review
- 05/13/2020 Medical Policy Implementation Committee approval. Title changed from “Sex Reassignment Surgery” to “Gender Reassignment Surgery” Document contents changed to replace “sex reassignment” with “gender reassignment”, “his or her” with “their” and “transsexual” with “transgender”. Clarified the eligible for coverage statement regarding hair removal procedures.
- 05/06/2021 Medical Policy Committee review

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Gender Affirming Surgery

Policy # 00643

Original Effective Date: 12/19/2018

Current Effective Date: 10/14/2024

- 05/12/2021 Medical Policy Implementation Committee approval. Added penile prostheses to eligible for coverage statement addressing phalloplasty procedures. Added a reference to see Further Considerations that are noted at the end of the coverage for bilateral mastectomy for individuals under 18 years of age. Clarified the criteria for bilateral mastectomy with the revision that one letter, signed by the referring qualified mental health professional who has independently assessed the individual is required. Added a *Note* that *Cosmetic procedures are considered an exclusion in most member contracts under the When Services Are Not Covered* section.
- 02/16/2022 Coding update
- 07/07/2022 Medical Policy Committee review
- 07/13/2022 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
- 09/01/2022 Medical Policy Committee review
- 09/14/2022 Medical Policy Implementation Committee approval. Title changed from “Gender Reassignment Surgery” to “Gender Affirming Surgery”. Replaced Reassignment” to “Affirming” throughout the policy. Extensive revisions made throughout the policy.
- 09/07/2023 Medical Policy Committee review
- 09/13/2023 Medical Policy Implementation Committee approval. Removed the When Services Are Eligible for Coverage section and moved the statements to the When Services May Be Eligible for Coverage section, since criteria apply. Removed the Note under the When Services May Be Eligible for Coverage section regarding chest, groin and reproductive organ procedures since it will be addressed in the Rationale/Source section. Removed the sub criteria in each set of coverage criteria for individuals diagnosed with gender dysphoria and referenced the Policy Guidelines section. Revised the Further Considerations section as follows: added “permitted by state law” regarding a bilateral mastectomy in an individuals under 18 years old; Removed information for WPATH SOC7; added WPATH SOC8 surgical criteria; and added a paragraph regarding potential shifts in gender-related experiences and needs during adolescence. Removed voice therapy from the services that are not covered, since it is not a surgical procedure. Deleted the specifications for the criteria and the post transition information from the Policy Guidelines. Updated the Policy Guidelines to and the rest of the policy regarding

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Gender Affirming Surgery

Policy # 00643

Original Effective Date: 12/19/2018

Current Effective Date: 10/14/2024

WPATH SOC8. Added references for the American Psychiatric Association and the International Journal of Transgender Health Standard of Care Version 8.

09/05/2024 Medical Policy Committee review

09/11/2024 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.

Next Scheduled Review Date: 09/2025

Coding

The five character codes included in the Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines are obtained from Current Procedural Terminology (CPT®)‡, copyright 2023 by the American Medical Association (AMA). CPT is developed by the AMA as a listing of descriptive terms and five character identifying codes and modifiers for reporting medical services and procedures performed by physician.

The responsibility for the content of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines is with Blue Cross and Blue Shield of Louisiana and no endorsement by the AMA is intended or should be implied. The AMA disclaims responsibility for any consequences or liability attributable or related to any use, nonuse or interpretation of information contained in Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein. Any use of CPT outside of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines should refer to the most current Current Procedural Terminology which contains the complete and most current listing of CPT codes and descriptive terms. Applicable FARS/DFARS apply.

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Gender Affirming Surgery

Policy # 00643

Original Effective Date: 12/19/2018

Current Effective Date: 10/14/2024

CPT is a registered trademark of the American Medical Association.

Codes used to identify services associated with this policy may include (but may not be limited to) the following:

Code Type	Code
CPT	11920, 11921, 11922, 17380, 17999, 19303, 19325, 19350, 53410, 53420, 53425, 53430, 54125, 54400, 54401, 54405, 54520, 54660, 54690, 55180, 55899, 55970, 55980, 56625, 56800, 56805, 57110, 57291, 57292, 57295, 57296, 57335, 57426, 58150, 58552, 58553, 58554, 58570, 58571, 58572, 58573
HCPCS	C1813, C2622, L8699
ICD-10 Diagnosis	F64.0-F64.9, F66, Z87.890

**Medically Necessary (or “Medical Necessity”) - Health care services, treatment, procedures, equipment, drugs, devices, items or supplies that a Provider, exercising prudent clinical judgment, would provide to a patient for the purpose of preventing, evaluating, diagnosing or treating an illness, injury, disease or its symptoms, and that are:

- A. In accordance with nationally accepted standards of medical practice;
- B. Clinically appropriate, in terms of type, frequency, extent, level of care, site and duration, and considered effective for the patient's illness, injury or disease; and
- C. Not primarily for the personal comfort or convenience of the patient, physician or other health care provider, and not more costly than an alternative service or sequence of services at least as likely to produce equivalent therapeutic or diagnostic results as to the diagnosis or treatment of that patient's illness, injury or disease.

For these purposes, “nationally accepted standards of medical practice” means standards that are based on credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community, Physician Specialty Society recommendations and the views of Physicians practicing in relevant clinical areas and any other relevant factors.

‡ Indicated trademarks are the registered trademarks of their respective owners.



Louisiana

Gender Affirming Surgery

Policy # 00643

Original Effective Date: 12/19/2018

Current Effective Date: 10/14/2024

NOTICE: If the Patient's health insurance contract contains language that differs from the BCBSLA Medical Policy definition noted above, the definition in the health insurance contract will be relied upon for specific coverage determinations.

NOTICE: Medical Policies are scientific based opinions, provided solely for coverage and informational purposes. Medical Policies should not be construed to suggest that the Company recommends, advocates, requires, encourages, or discourages any particular treatment, procedure, or service, or any particular course of treatment, procedure, or service.

NOTICE: Federal and State law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage.

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.